
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Synthetic cannabinoids and cathinones have become drugs of abuse for adolescents and young adults. Research suggests that there is potential for great harm with chronic use.






